

What is claimed is:

1. A composition comprising an isolated protein encoded by a polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 186 to nucleotide 1532;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 261 to nucleotide 1532;
 - (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 255 to nucleotide 1532;
 - (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AK647 deposited under accession number ATCC 98026;
 - (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AK647 deposited under accession number ATCC 98026;
 - (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AK647 deposited under accession number ATCC 98026;
 - (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AK647 deposited under accession number ATCC 98026;
 - (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
 - (j) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 24 to amino acid 448;
 - (k) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 26 to amino acid 448;
 - (l) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity;
 - (m) a polynucleotide which is an allelic variant of a polynucleotide of any of (a)-(h) above; and
 - (n) a polynucleotide which encodes a species homologue of the protein of any of (i)-(k) above.
2. The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

3. A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 2.

4. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 104;
- (c) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 93;
- (d) the amino acid sequence of SEQ ID NO:2 from amino acid 24 to amino acid 448;
- (e) the amino acid sequence of SEQ ID NO:2 from amino acid 26 to amino acid 448;
- (f) fragments of the amino acid sequence of SEQ ID NO:2; and
- (g) the amino acid sequence encoded by the cDNA insert of clone AK647 deposited under accession number ATCC 98026;

the protein being substantially free from other mammalian proteins.

5. A method for promoting smooth muscle cell growth or vasculogenesis which comprises administering to a mammalian subject a therapeutically effective amount of an antibody of claim 11.

6. A method for promoting smooth muscle cell growth or vasculogenesis which comprises administering to a mammalian subject a therapeutically effective amount of an antibody of claim 12.

7. The composition of claim 4, further comprising a pharmaceutically acceptable carrier.

8. A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 7.

9. The method of claim 3 wherein said medical condition is selected from the group consisting of smooth muscle cell growth, vasculogenesis and restenosis.

10. The method of claim 8 wherein said medical condition is selected from the group consisting of smooth muscle cell growth, vasculogenesis and restenosis.

11. An anitbody or antibody fragment which reacts with the protein of claim 1.

12. An anitbody or antibody fragment which reacts with the protein of claim 4.